Could Valeant Pharmaceuticals Intl Inc Gain Strenght? The Stock Reaches All-Time Low

 Could Valeant Pharmaceuticals Intl Inc Gain Strenght? The Stock Reaches All Time Low

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) reached all time low today, Nov, 8 and still has $18.46 target or 8.00% below today’s $20.06 share price. This indicates more downside for the $6.78B company. This technical setup was reported by Barchart.com. If the $18.46 PT is reached, the company will be worth $542.40M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 952,369 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 29.58% since April 1, 2016 and is downtrending. It has underperformed by 31.53% the S&P500.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 2 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $74 is the highest target while $38 is the lowest. The $42.50 average target is 111.86% above today’s ($20.06) stock price. Valeant Pharmaceuticals International has been the topic of 14 analyst reports since October 20, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock with “Sector Perform” rating in Tuesday, October 25 report. On Monday, June 27 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. As per Tuesday, October 20, the company rating was maintained by RBC Capital Markets. TD Securities maintained the stock with “Buy” rating in Thursday, August 11 report. The firm has “Sector Perform” rating given on Tuesday, October 11 by RBC Capital Markets. On Tuesday, January 26 the stock rating was maintained by RBC Capital Markets with “Outperform”. As per Wednesday, July 20, the company rating was maintained by TD Securities. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, May 24. The firm has “Sector Perform” rating by RBC Capital Markets given on Monday, June 20. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, September 7.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Fool.com with their article: “Another Month, Another 27% Decline for Valeant Pharmaceuticals Intl. Inc. in …” published on November 07, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Investorplace.com‘s news article titled: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” with publication date: November 02, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $6.78 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment